Analogs of the pancreatic peptide hormone amylin are making strides in obesity as developers zoom in on oral drugs that can emulate or even improve on injectable GLP-1 agonists while avoiding muscle loss and gastrointestinal troubles.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Buy this article
Purchase on SpringerLink
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Author information Authors and Affiliations Canterbury, UK
Charlotte Harrison
Authors
Charlotte Harrison Rights and permissions About this article
Cite this article Harrison, C. Can amylin-based drugs upstage GLP-1 agonists?.
Nat Biotechnol (2025). https://doi.org/10.1038/s41587-025-02778-7
Download citation
Published: 05 August 2025
DOI : https://doi.org/10.1038/s41587-025-02778-7
Leave a Reply